<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20250629066291N7</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-09-28</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>The effect of adding a mechanical plantar massager to routine physiotherapy on pain intensity and function in patients with plantar fasciitis: a single-blind randomized controlled trial</public_title>
      <acronym></acronym>
      <scientific_title>The effect of adding a mechanical plantar massager to routine physiotherapy on pain intensity and function in patients with plantar fasciitis: a single-blind randomized controlled trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-10-27</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>54</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/93488</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Participants will be allocated to the intervention and control groups using block randomization with variable block sizes and a 1:1 allocation ratio. The randomization sequence will be generated by an individual independent of participant recruitment and intervention delivery. To ensure allocation concealment, the sequence will be placed in sequentially numbered, opaque, sealed envelopes (SNOSE). After completion of each participant's baseline assessments and confirmation of eligibility, the corresponding envelope will be opened in numerical order to reveal group allocation, Blinding description: This study will be conducted as a single-blind randomized controlled trial. In this design, the outcome assessor will be blinded to participants' group allocation and the type of intervention received. Pre- and post-intervention assessments will be performed by a trained assessor independent of the treatment delivery process. To maintain assessor blinding, participants will be instructed not to disclose the type of intervention received to the assessor during outcome assessments. Given the nature of the interventions (exercise therapy, myofascial release, and use of the home-based mechanical device), blinding of participants and the treating therapist to the intervention type will not be feasible.</study_design>
      <phase>N/A</phase>
      <hc_freetext>plantar fasciitis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:. Intervention 2: Control group:.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Information collection form including primary and secondary outcomes, informed consent form and SSPS file.

When:
After publication of the results of the study

To whom:
Researchers working in academic and scientific institutions

Conditions:
Only for recording information in scientific databases

Where to obtain:
correspondence with the project manager by email. Haghighat_fa@yahoo.com

How to obtain:
Maximum one month after sending the request by email.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Farzaneh Haghighat</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Chamran Blvd</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7194815644</zip>
        <telephone>+98 71 3230 5410</telephone>
        <email>Haghighat_fa@yahoo.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Farzaneh Haghighat</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Mehr Building, Shahid Chamran Hospital, Shahid Chamran Boulevard</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7194815644</zip>
        <telephone>+98 71 3624 0101</telephone>
        <email>haghighat_fa@yahoo.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age between 18 and 65 years
Clinical diagnosis of plantar fasciopathy based on pain in the plantar and medial heel region, particularly at the site of insertion of the plantar fascia into the medial calcaneal tuberosity, accompanied by exacerbation of pain during the first steps after waking up or after a period of rest
Presence of localized tenderness to palpation at the site of insertion of the plantar fascia into the medial calcaneal tuberosity on clinical examination
Duration of symptoms of at least three months prior to enrollment, in order to select individuals with chronic plantar fasciopathy
Ability to walk independently and to perform the exercise therapy program and interventions specified in the study
Willingness to participate in the study and to complete the informed consent form</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Presence of symptoms or findings inconsistent with a clinical diagnosis of plantar fasciopathy, or suggestive of other causes of heel pain, including calcaneal fracture or stress fracture, heel fat pad disorders, peripheral nerve irritation or entrapment, and other known causes of heel pain
Presence of symptoms or clinical findings suggestive of nerve involvement, including numbness, tingling, radiating pain, or other sensory symptoms indicating possible neural involvement or a non-local origin of pain
Presence of known inflammatory or systemic diseases that could contribute to heel pain or foot dysfunction and that could affect the diagnosis or assessment of study outcomes, including spondyloarthropathies
History of surgery on the affected foot or ankle, or history of severe lower limb injury with a significant effect on foot function or gait pattern
Presence of a known plantar fascia rupture or other defined structural injuries of the foot and ankle that would render the study interventions inappropriate
Receipt of any specific therapeutic intervention outside the study protocol for plantar fasciopathy that continues concurrently with the start of the study and cannot be discontinued or controlled during the intervention period
Presence of overt structural foot abnormalities, including pes planus or pes cavus, observed and confirmed on clinical assessment</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M72.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Plantar fascial fibromatosis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:</i_keyword>
      <i_keyword>Control group:</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Heel pain intensity. Timepoint: Pain during the day and pain during the first steps in the morning. Method of measurement: The Visual Analogue Scale (0–10).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Foot and ankle function (FAAM). Timepoint: Before the intervention, immediately after the 4-week treatment period, and 4 weeks after completion of treatment. Method of measurement: FAAM questionnaire (21-item ADL subscale); each item scored 0 (unable to perform) to 4 (no difficulty); lower scores indicate greater functional limitation.</sec_outcome>
      <sec_outcome>Pressure pain threshold of the plantar surface. Timepoint: Before the intervention, immediately after the 4-week treatment period, and 4 weeks after completion of treatment. Method of measurement: Pressure algometer; patient prone, the most tender plantar point marked, algometer applied perpendicular to the point at approximately 1 kg/s; the moment pain is first felt is recorded; two measurements 3 minutes apart, averaged.</sec_outcome>
      <sec_outcome>Ankle dorsiflexion range of motion. Timepoint: Before the intervention, immediately after the 4-week treatment period, and 4 weeks after completion of treatment. Method of measurement: Standard goniometer; patient sitting on the treatment table, the tested knee in full extension, the opposite limb hanging off the edge of the table.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-10-11</approval_date>
        <contact_name>Ethics committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>Ethics committee, Research and Technology Vice-Chancellor, 7th floor, Central building of Shiraz University of Medical Sciences, Zand Street Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
